Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ella Webster

Rheumatology Albuquerque, NM Medical Doctor

NPI 1942367982 CMS profile 87808

2901 Transport St Se, Albuquerque, NM 87106

Open in the dashboard

General payments

$591

25 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ella Webster of Albuquerque, NM is reported in the CMS Open Payments database as having received $591 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $134 1
2022 General $229 13
2021 General $159 9
2019 General $69 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ella Webster
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Ella Webster were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Ella Webster Rheumatology median Middle half National median
2019 $69 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $159 $531 $101–$2,153 $132
2022 $229 $627 $125–$2,303 $149
2023 $134 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Amgen Inc. $157 7 payments
  2. AstraZeneca Pharmaceuticals LP $134 1 payment
  3. Janssen Biotech, Inc. $110 6 payments
  4. Novartis Pharmaceuticals Corporation $68 4 payments
  5. Lilly USA, LLC $20 1 payment
  6. Gilead Sciences, Inc. $20 1 payment
  7. E.R. Squibb & Sons, L.L.C. $19 1 payment
  8. Mallinckrodt Hospital Products Inc. $19 1 payment
  9. Fresenius USA Marketing, Inc. $18 1 payment
  10. Pfizer Inc. $14 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $551 23 payments
  2. Education $40 2 payments
Products named General payments · program years 2019–2023
  1. SAPHNELO $134 1 payment
  2. Tavneos $74 4 payments
  3. SIMPONI ARIA $72 4 payments
  4. TREMFYA $61 3 payments
  5. Enbrel $49 1 payment
  6. SIMPONI $49 3 payments
  7. STELARA $49 3 payments
  8. REMICADE $49 3 payments
  9. COSENTYX $48 3 payments
  10. Otezla $33 2 payments
  11. Other $190 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

500

Median for Rheumatology: 1,511

Drug cost

$530,793

Median for Rheumatology: $1,139,948

Branded share of claims

39.4%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 35 $257,332
Enbrel Sureclick Etanercept Brand 25 $216,705
Actemra Tocilizumab Brand 15 $43,550
Hydroxychloroquine Sulfate Generic 85 $3,880
Methotrexate Methotrexate Sodium Brand 122 $3,360
Colchicine Generic 16 $1,973
Prednisone Generic 108 $1,424
Mycophenolate Mofetil Generic 11 $778
Leflunomide Generic 13 $712
Leucovorin Calcium Generic 28 $663

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$366,832

Of which drugs: $350,638

Medicare patients

154

Average age 71

Services billed

29,625

110 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 64%
High blood pressure 55%
Osteoporosis 34%
Depression 30%
Chronic kidney disease 24%
Diabetes 21%
Ischemic heart disease 19%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg Q5104 Office 15 1,050 $25,063
Injection, zoledronic acid, 1 mg J3489 Office 20 100 $413

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record